Beyond The Numbers: 6 Analysts Discuss BeOne Medicines Stock

During the last three months, 6 analysts shared their evaluations of BeOne Medicines (NASDAQ:ONC), revealing diverse outlooks from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	2	4	0	0	0
Last 30D	0	1	0	0	0
1M Ago	0	0	0	0	0
2M Ago	0	0	0	0	0
3M Ago	2	3	0	0	0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $399.67, with a high estimate of $408.00 and a low estimate of $394.00. This upward trend is evident, with the current average reflecting a 5.12% increase from the previous average price target of $380.20.

Decoding Analyst Ratings: A Detailed Look

The perception of BeOne Medicines by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Peter Lawson	Barclays	Raises	Overweight	$394.00	$385.00
Gregory Renza	Truist Securities	Announces	Buy	$400.00	-
Leonid Timashev	RBC Capital	Raises	Outperform	$408.00	$395.00
Yigal Nochomovitz	Citigroup	Raises	Buy	$405.00	$399.00
Leonid Timashev	RBC Capital	Raises	Outperform	$395.00	$374.00
Reni J. Benjamin	Citizens	Raises	Market Outperform	$396.00	$348.00

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BeOne Medicines. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BeOne Medicines compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of BeOne Medicines's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BeOne Medicines's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on BeOne Medicines analyst ratings.

Get to Know BeOne Medicines Better

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

BeOne Medicines's Financial Performance

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3M period, BeOne Medicines showcased positive performance, achieving a revenue growth rate of 41.0% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: BeOne Medicines's net margin is impressive, surpassing industry averages. With a net margin of 8.84%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): BeOne Medicines's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.16%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.79%, the company showcases effective utilization of assets.

Debt Management: With a below-average debt-to-equity ratio of 0.25, BeOne Medicines adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.